Melanoma, version 4.2014: Featured updates to the NCCN guidelines

Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. OlszanskiMerrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, Maria Ho

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations

Abstract

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

Original languageEnglish (US)
Pages (from-to)621-629
Number of pages9
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number5
DOIs
StatePublished - 2014

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Melanoma, version 4.2014: Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this